MGX (Metagenomi Therapeutics) Interest Expense: $0.00 Mil (TTM As of Mar. 2026)


MGX Metagenomi Therapeutics Inc MGX
10 GF Score
Price $1.29
! 4 Warning Signs
View Full Analysis

What is Metagenomi Therapeutics Interest Expense?

Metagenomi Therapeutics MGX -2.27% 10 Interest Expense is $0.00 Mil as of Mar. 2026. GuruFocus rates MGX with a GF Score™ of 10/100. The stock has 4 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Metagenomi Therapeutics's interest expense for the three months ended in Mar. 2026 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Metagenomi Therapeutics's Operating Income for the three months ended in Mar. 2026 was $ -24.59 Mil. Metagenomi Therapeutics's Interest Expense for the three months ended in Mar. 2026 was $ 0.00 Mil. GuruFocus does not calculate Metagenomi Therapeutics's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Metagenomi Therapeutics  (NAS:MGX) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Metagenomi Therapeutics's Interest Expense for the three months ended in Mar. 2026 was $0.00 Mil. Its Operating Income for the three months ended in Mar. 2026 was $-24.59 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was $33.08 Mil.

Metagenomi Therapeutics's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

GuruFocus does not calculate Metagenomi Therapeutics's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Metagenomi Therapeutics Inc has enough cash to cover all of its debt. Its financial situation is stable.

Metagenomi Therapeutics Interest Expense Historical Data

* Premium members only.

The historical data trend for Metagenomi Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Metagenomi Therapeutics Interest Expense Chart

Metagenomi Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
-0.30 -0.10 0.00 0.00 0.00

Metagenomi Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MGX
10GF Score
Metagenomi Therapeutics Inc MGX
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Metagenomi Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of $0.00 Mil mean?
Metagenomi Therapeutics (MGX) has a Interest Expense of $0.00 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Metagenomi Therapeutics and its competitors.
Is Metagenomi Therapeutics' Interest Expense too high?
Metagenomi Therapeutics' current Interest Expense is $0.00 Mil. Overall, Metagenomi Therapeutics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Metagenomi Therapeutics' Interest Expense compare to KALA and HYPD?
Metagenomi Therapeutics' Interest Expense of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Metagenomi Therapeutics and its competitors. Metagenomi Therapeutics's current Interest Expense is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metagenomi Therapeutics stock overvalued right now?
Metagenomi Therapeutics (MGX) has a current Interest Expense of $0.00 Mil. The current Interest Expense is $0.00 Mil. Metagenomi Therapeutics' overall GF Score™ is 10/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Metagenomi Therapeutics (MGX), the current Interest Expense is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Metagenomi Therapeutics Business Description

Address 5959 Horton Street, 7th Floor, Emeryville, CA, USA, 94608
Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.
10GF Score

Get the complete analysis for MGX

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.29
Price